Individuals, especially east Asians who carry a mutation in a key enzyme involved in alcohol metabolism, have an increased risk of developing Alzheimer’s disease as a consequence of regular alcohol consumption, according to recent research. The study, “Aldehyde dehydrogenase 2 activity and aldehydic load contribute to neuroinflammation and Alzheimer’s…
Higher concentrations of a protein produced exclusively by the brain’s immune cells, called TREM2, may prevent memory decline and lessen brain degeneration in people with Alzheimer’s disease, according to a recent study. The results of the study, “Increased soluble TREM2 in cerebrospinal fluid is associated with reduced…
Compared to regular amyloid imaging, fluorodeoxyglucose positron emission tomography (FDG PET), an imaging technique that quantifies brain function by measuring glucose levels, can better assess the progression and severity of cognitive decline in people with Alzheimer’s, and also cognitive impairment, researchers have found. Their study, “18F-FDG Is…
Spontaneous seizures reduce the production of new brain cells, and result in poor spatial discrimination — a common occurrence in people with Alzheimer’s disease, according to a mouse study. The study, “Early Seizure Activity Accelerates Depletion of Hippocampal Neural Stem Cells and Impairs Spatial Discrimination in an Alzheimer’s…
ProMIS Neurosciences’ candidate PMN310 can specifically target toxic clusters of soluble amyloid-beta protein, and be safely administered at high doses with reduced risk of characteristic Alzheimer’s brain changes or swelling, according to clinical data. PMN310 has the potential for greater therapeutic potency compared with other amyloid-beta-directed antibodies…
ProMIS Neurosciences researchers have discovered new antibody candidates that selectively bind to the neurotoxic form of the tau protein — one of the hallmarks of Alzheimer’s disease. These new antibodies join the company’s PMN310, a humanized antibody that attacks only toxic forms of the amyloid beta protein…
Tau bio-logic and LifeArc researchers have generated a human-like antibody called TBL-100 for the treatment of Alzheimer’s disease (AD) and progressive supranuclear palsy (PSP). An antibody is a large Y-shaped protein that’s naturally produced in response to invading foreign particles (antigens) such as viruses. A humanized…
A cellular model that simulates the blood-brain barrier — a membrane that protects against viruses or other insults entering through the blood stream — may help in understanding how potential treatments for neurological diseases like Alzheimer’s could better cross that barrier to reach the brain and central nervous system, its creators…
Porphyomonas gingivalis, a bacteria that causes a type of gum disease known as chronic periodontitis, was found in the brains of Alzheimer’s patients, providing evidence of its possible role in the disease’s development, a study reports. The release of toxic enzymes from this bacteria was blocked by a…
Changes in brain cells known as astrocytes mirror transformations in Alzheimer’s disease, and may contribute to patients’ nerve cell degeneration, a Finnish study reports. It is the first time that research has shown that astrocytes may contribute to Alzheimer’s. The University of Eastern Finland team published their work, “PSEN1 Mutant iPSC-Derived Model…
Get regular updates to your inbox.